Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Cesson Sevigne Cedex, France Clinical Trials

A listing of Cesson Sevigne Cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (6) clinical trials

Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)

Open label, Phase II, prospective, multicentric, randomized study 2:1, 2 arm study designed to evaluate the efficacy of a Stereotactic Body Radiation Therapy treatment associated with immunotherapy versus a Stereotactic Body Radiation Therapy treatment only. Primary objective The primary objective is to evaluate the efficacy, in term of progression-free survival …

Phase

3.46 miles

Learn More »

COVID-19 and Chilblains

Chilblains (inflammatory lesion of the feet or hands) have been reported with an unusual frequency during the confinement period, most commonly in children, teenagers and young adults. The aim of the ECCES study is to find out whether these manifestations of chilblains can be linked to the SARS-CoV-2 coronavirus. For …

Phase N/A

3.46 miles

Learn More »

Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

In 2014, the International Myeloma Working Group (IMWG) proposed a revised classification of multiple myeloma (MM) and smoldering myeloma (SMM). Since the new definition of SMM proposed excludes "ultra-high risk SMM", the evolution profile of SMM will change. Therefore, investigators need to update their knowledge of SMM to optimize the …

Phase N/A

3.46 miles

Learn More »

Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Treatment of non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutation is mainly based on tyrosine kinase inhibitors (TKIs) targeting EGFR. 1st or 2nd generation inhibitors have been shown to be superior to chemotherapy in terms of Progression-Free Survival (PFS) when used as 1st line treatment. In …

Phase

3.46 miles

Learn More »

Study Association of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

This is a phase II, multicenter, non-randomized, open-label study to evaluate the safety and efficacy of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in patients with newly diagnosed multiple myeloma. The patient population will consist of adult men and women 65 years, who have a confirmed diagnosis of standard risk multiple myeloma, …

Phase

3.46 miles

Learn More »

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

Carcinosarcomas (CS) (malignant mixed Mllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) < 10% and a poor prognosis. After initial treatment (surgery +/- adjuvant radiotherapies …

Phase

4.83 miles

Learn More »